EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expression and prognosis of inducible T‐cell co‐stimulator and its ligand in Chinese stage I–III lung adenocarcinoma patients

Xiao-Kai Zhan, Xi-Kun Liu, Sen Zhang iD, Hong Chen

Animal Models and Experimental Medicine · 2023

DOI: 10.1002/ame2.12355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2023. Verfasst von Xiao-Kai Zhan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology and Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Inducible T-Cell Co-Stimulator Protein, Inducible T-Cell Co-Stimulator Ligand. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy has become the fastest‐adopting treatment paradigm for lung cancer with improved survival. By binding with its ligand (inducible T‐cell co‐stimulator and its ligand [ICOSL]), an inducible T‐cell co‐stimulator (ICOS) could contribute to reversing immunosuppression and improving immune response and thus be a potential target for cancer immunotherapy.

Methods

We selected 54 formalin‐fixed, paraffin‐embedded tumor tissues from cases with stage I–III lung adenocarcinoma cancer. Immunohistochemical expression of ICOS and ICOSL was evaluated. The correlation with clinical parameters in Chinese patients was also compared with TCGA results.

Results

The positive rates of ICOS and ICOSL were 68% and 81.5%, respectively, in lung tumor tissues. Of these, 9 cases had a low expression of ICOS, and 22 cases had a high expression of ICOS; ICOSL expression was low in 20 cases and high in 24 cases. According to the International Association for the Study of Lung Cancer (8th edition), phase I lesions were detected in 21 cases, phase II lesions in 15 cases, and phase III lesions in 18 cases. The median survival time of all patients was 44.5 months, and the median disease‐free survival was 32 months. Univariate analysis showed that the factors significantly associated with overall survival were tumor size, regional lymph node involvement, stage, and expression level of ICOS/ICOSL. Survival analysis using log‐rank test indicated that the lower ICOS+ cell infiltration may predict poor prognosis, whereas lower ICOSL protein expression may be associated with better prognosis, but ICOSL data need further validation in larger samples due to inconsistency in TCGA mRNA prediction.

Conclusion

ICOS/ICOSL might be associated with prognosis of lung cancer, and ICOS and its ligand may be potential therapeutic targets in non‐small cell lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungInducible T-Cell Co-Stimulator ProteinInducible T-Cell Co-Stimulator LigandHumansEast Asian PeopleLigandsLung NeoplasmsPrognosis

Stichwörter der Autor:innen

Chinese patientsICOSICOSLlung adenocarcinomaprognostic factor

Substanzen

Inducible T-Cell Co-Stimulator ProteinLigandsInducible T-Cell Co-Stimulator Ligand

Autor:innen und Institutionen

  • Division of Oncology and Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China.
  • State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.
  • Pathology Department, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China.

ORCID-Profile: Sen Zhang

Zitieren

APA

Zhan, X. K., Liu, X. K., Zhang, S., & Chen, H. (2023). Expression and prognosis of inducible T‐cell co‐stimulator and its ligand in Chinese stage I–III lung adenocarcinoma patients. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12355

Vancouver

Zhan XK, Liu XK, Zhang S, Chen H. Expression and prognosis of inducible T‐cell co‐stimulator and its ligand in Chinese stage I–III lung adenocarcinoma patients. Animal Models and Experimental Medicine. 2023. doi:10.1002/ame2.12355

BibTeX
@article{Zhan2023,
  author = {Zhan, Xiao-Kai and Liu, Xi-Kun and Zhang, Sen and Chen, Hong},
  title = {Expression and prognosis of inducible T‐cell co‐stimulator and its ligand in Chinese stage I–III lung adenocarcinoma patients},
  journal = {Animal Models and Experimental Medicine},
  year = {2023},
  doi = {10.1002/ame2.12355}
}
Kostenlos starten →